143 related articles for article (PubMed ID: 34866168)
1. Clinical Pharmacokinetics of the Androgen Receptor Inhibitor Darolutamide in Healthy Subjects and Patients with Hepatic or Renal Impairment.
Zurth C; Nykänen P; Wilkinson G; Taavitsainen P; Vuorela A; Huang F; Reschke S; Koskinen M
Clin Pharmacokinet; 2022 Apr; 61(4):565-575. PubMed ID: 34866168
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of Darolutamide, its Diastereomers and Active Metabolite in the Mouse: Response to Saini NK et al. (2020).
Nykänen P; Korjamo T; Gieschen H; Zurth C; Koskinen M
Drug Metab Lett; 2021; 14(1):9-16. PubMed ID: 33183216
[TBL] [Abstract][Full Text] [Related]
3. Phase 1 study of darolutamide (ODM-201): a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer.
Matsubara N; Mukai H; Hosono A; Onomura M; Sasaki M; Yajima Y; Hashizume K; Yasuda M; Uemura M; Zurth C
Cancer Chemother Pharmacol; 2017 Dec; 80(6):1063-1072. PubMed ID: 28801852
[TBL] [Abstract][Full Text] [Related]
4. Metabolism and Mass Balance of the Novel Nonsteroidal Androgen Receptor Inhibitor Darolutamide in Humans.
Taavitsainen P; Prien O; Kähkönen M; Niehues M; Korjamo T; Denner K; Nykänen P; Vuorela A; Jungmann NA; von Bühler CJ; Koskinen M; Zurth C; Gieschen H
Drug Metab Dispos; 2021 Jun; 49(6):420-433. PubMed ID: 33785516
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Clinically Relevant Drug-Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial.
Shore N; Zurth C; Fricke R; Gieschen H; Graudenz K; Koskinen M; Ploeger B; Moss J; Prien O; Borghesi G; Petrenciuc O; Tammela TL; Kuss I; Verholen F; Smith MR; Fizazi K
Target Oncol; 2019 Oct; 14(5):527-539. PubMed ID: 31571095
[TBL] [Abstract][Full Text] [Related]
6. Clinical Pharmacokinetics and Pharmacodynamics of the Next Generation Androgen Receptor Inhibitor-Darolutamide.
Podgoršek E; Mehra N; van Oort IM; Somford DM; Boerrigter E; van Erp NP
Clin Pharmacokinet; 2023 Aug; 62(8):1049-1061. PubMed ID: 37458966
[TBL] [Abstract][Full Text] [Related]
7. Darolutamide is a potent androgen receptor antagonist with strong efficacy in prostate cancer models.
Sugawara T; Baumgart SJ; Nevedomskaya E; Reichert K; Steuber H; Lejeune P; Mumberg D; Haendler B
Int J Cancer; 2019 Sep; 145(5):1382-1394. PubMed ID: 30828788
[TBL] [Abstract][Full Text] [Related]
8. Darolutamide for treatment of castration-resistant prostate cancer.
Rhea LP; Mendez-Marti S; Aragon-Ching JB
Drugs Today (Barc); 2020 Mar; 56(3):185-193. PubMed ID: 32282865
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of Darolutamide in Mouse - Assessment of the Disposition of the Diastereomers, Key Active Metabolite and Interconversion Phenomenon: Implications to Cancer Patients.
Saini NK; Gabani BB; Todmal U; Sulochana SP; Kiran V; Zainuddin M; Balaji N; Polina SB; Srinivas NR; Mullangi R
Drug Metab Lett; 2021; 14(1):54-65. PubMed ID: 32436836
[TBL] [Abstract][Full Text] [Related]
10. An up-to-date evaluation of darolutamide for the treatment of prostate cancer.
Moussa M; Lazarou L; Dellis A; Abou Chakra M; Papatsoris A
Expert Opin Pharmacother; 2021 Mar; 22(4):397-402. PubMed ID: 33135506
[No Abstract] [Full Text] [Related]
11. Absorption, distribution, metabolism and excretion of darolutamide (a novel non-steroidal androgen receptor antagonist) in rats.
Taavitsainen P; Gieschen H; Korjamo T; Kähkönen M; Malmström C; Prien O; Niehues M; Sandmann S; Janssen W; Koskinen M
Xenobiotica; 2020 Aug; 50(8):967-979. PubMed ID: 32003293
[TBL] [Abstract][Full Text] [Related]
12. Darolutamide (ODM-201) for the treatment of prostate cancer.
Shore ND
Expert Opin Pharmacother; 2017 Jun; 18(9):945-952. PubMed ID: 28490267
[TBL] [Abstract][Full Text] [Related]
13. Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer.
Fizazi K; Smith MR; Tombal B
Clin Genitourin Cancer; 2018 Oct; 16(5):332-340. PubMed ID: 30197098
[TBL] [Abstract][Full Text] [Related]
14. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
Borgmann H; Lallous N; Ozistanbullu D; Beraldi E; Paul N; Dalal K; Fazli L; Haferkamp A; Lejeune P; Cherkasov A; Gleave ME
Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578
[TBL] [Abstract][Full Text] [Related]
15. Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide.
Fizazi K; Shore N; Tammela TL; Ulys A; Vjaters E; Polyakov S; Jievaltas M; Luz M; Alekseev B; Kuss I; Le Berre MA; Petrenciuc O; Snapir A; Sarapohja T; Smith MR;
N Engl J Med; 2020 Sep; 383(11):1040-1049. PubMed ID: 32905676
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy with novel androgen receptor antagonists and statin for castration-resistant prostate cancer.
Nakayama H; Sekine Y; Oka D; Miyazawa Y; Arai S; Koike H; Matsui H; Shibata Y; Suzuki K
Prostate; 2022 Feb; 82(3):314-322. PubMed ID: 34843630
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of darolutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a sub-group analysis of the phase III ARAMIS trial.
Uemura H; Matsushima H; Kobayashi K; Mizusawa H; Nishimatsu H; Fizazi K; Smith M; Shore N; Tammela T; Tabata KI; Matsubara N; Iinuma M; Uemura H; Oya M; Momma T; Kawakita M; Fukasawa S; Kobayashi T; Kuss I; Le Berre MA; Snapir A; Sarapohja T; Suzuki K
Int J Clin Oncol; 2021 Mar; 26(3):578-590. PubMed ID: 33226524
[TBL] [Abstract][Full Text] [Related]
18. Drug-Drug Interaction Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Ipatasertib in Combination with Darolutamide in Patients with Advanced Prostate Cancer.
Sutaria DS; Rasuo G; Harris A; Johnson R; Miles D; Gallo JD; Sane R
Pharmaceutics; 2022 Oct; 14(10):. PubMed ID: 36297536
[TBL] [Abstract][Full Text] [Related]
19. Drug-Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies.
Zurth C; Koskinen M; Fricke R; Prien O; Korjamo T; Graudenz K; Denner K; Bairlein M; von Bühler CJ; Wilkinson G; Gieschen H
Eur J Drug Metab Pharmacokinet; 2019 Dec; 44(6):747-759. PubMed ID: 31571146
[TBL] [Abstract][Full Text] [Related]
20. [Darolutamide: A new drug for non-metastatic castration-resistant prostate cancer].
Zhang F; Lu YP
Zhonghua Nan Ke Xue; 2020 Apr; 26(4):364-368. PubMed ID: 33351306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
